Rafael Holdings, Inc. RFL
We take great care to ensure that the data presented and summarized in this overview for Rafael Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RFL
View all-
Vanguard Group Inc Valley Forge, PA1MShares$2.11 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX338KShares$710,6940.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY336KShares$706,4250.71% of portfolio
-
Geode Capital Management, LLC Boston, MA261KShares$548,0160.0% of portfolio
-
Ieq Capital, LLC239KShares$501,6430.0% of portfolio
-
Black Rock Inc. New York, NY204KShares$429,4160.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA169KShares$355,84729.62% of portfolio
-
State Street Corp Boston, MA60.3KShares$126,5960.0% of portfolio
-
Cerity Partners LLC New York, NY44.8KShares$94,1550.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA38.8KShares$81,446100.0% of portfolio
Latest Institutional Activity in RFL
Top Purchases
Top Sells
About RFL
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Insider Transactions at RFL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2025
|
David Polinsky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,347
-0.87%
|
$2,347
$1.6 P/Share
|
|
Jun 13
2025
|
Howard S Jonas Exec Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
118,596
+29.93%
|
$237,192
$2.11 P/Share
|
|
Jun 05
2025
|
Howard S Jonas Exec Chairman, CEO & President |
BUY
Open market or private purchase
|
Indirect |
13,080,457
+50.0%
|
$13,080,457
$1.28 P/Share
|
|
May 29
2025
|
David Polinsky Chief Financial Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
76,882
+22.14%
|
$76,882
$1.28 P/Share
|
|
May 27
2025
|
Markus Sieger |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
35,000
+15.54%
|
$35,000
$1.28 P/Share
|
|
Mar 25
2025
|
William Conkling Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,454
+4.64%
|
-
|
|
Mar 21
2025
|
William Conkling Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,814
-2.68%
|
$14,814
$1.93 P/Share
|
|
Mar 21
2025
|
David Polinsky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,378
-1.21%
|
$2,378
$1.93 P/Share
|
|
Jan 13
2025
|
William Conkling Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+9.81%
|
$60,000
$1.95 P/Share
|
|
Jan 13
2025
|
John Goldberg CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
$50,000
$1.95 P/Share
|
|
Jan 13
2025
|
David Polinsky Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+20.33%
|
$50,000
$1.95 P/Share
|
|
Jan 06
2025
|
Mark N Stein |
BUY
Grant, award, or other acquisition
|
Direct |
11,475
+50.0%
|
$11,475
$1.82 P/Share
|
|
Jan 06
2025
|
Michael J Weiss |
BUY
Grant, award, or other acquisition
|
Direct |
27,541
+21.18%
|
$27,541
$1.82 P/Share
|
|
Jan 06
2025
|
Stephen M Greenberg |
BUY
Grant, award, or other acquisition
|
Direct |
27,541
+21.18%
|
$27,541
$1.82 P/Share
|
|
Dec 21
2024
|
William Conkling Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,807
-2.54%
|
$12,807
$1.84 P/Share
|
|
Dec 21
2024
|
David Polinsky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,002
-1.35%
|
$2,002
$1.84 P/Share
|
|
Oct 25
2024
|
William Conkling Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,431
-0.68%
|
$3,431
$1.84 P/Share
|
|
Oct 25
2024
|
David Polinsky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,331
-2.2%
|
$3,331
$1.84 P/Share
|
|
Sep 23
2024
|
David Polinsky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,431
-0.94%
|
$1,431
$1.73 P/Share
|
|
Sep 21
2024
|
David Polinsky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,384
-1.54%
|
$2,384
$1.73 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 373K shares |
|---|---|
| Open market or private purchase | 13.1M shares |
| Exercise of in-the-money or at-the-money derivatives securities | 112K shares |
| Payment of exercise price or tax liability | 57.6K shares |
|---|